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Genome analysis which takes into account tumor purity
leads to discovery of PTEN as a tumor suppressor gene
in high-grade serous ovarian cancer.ing transcribed. In order to avoid the analysis of tissueHigh-throughput approaches for molecular characterization
of biospecimens enable us to comprehensively dissect can-
cer cells. Cohort studies of clinical tumor samples have
provided valuable new insights, such as the discovery of
genes that drive cancer [1]. However, surgical resection of
tumor tissue often results in the inclusion of tumor-
adjacent normal cells and a tumor microenvironment.
As a consequence, the tissue samples under investigation
in genomic and transcriptomic studies reflect heterogen-
eity in the number of tumor cells actually analyzed [2].
Tumor purity may be an important determinant of our
ability to further uncover driver genes. In this issue of
Genome Biology, Brenton and colleagues aimed to ac-
count for tumor purity by estimating stromal content
in an unbiased fashion using in silico hematoxylin and
eosin (H&E) slide image analysis [3].
Defogging the ovarian carcinoma genome
The tumor microenvironment consists of immune cells,
endothelial cells and fibroblasts, and is commonly referred
to as tumor stroma. The stromal component contributes
to the pool of DNA and RNA molecules that are used for
genomic/transcriptomic analysis. While mutation analysis
is generally less affected as sequencing depth can account
for the relative proportion of tumor DNA, the diluting ef-
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leted in the tumor cells may appear as single copy loss
due to the admixture of stromal content. The same stro-
mal component may express the gene, thus creating the
impression of a hemizygously lost gene that is actively be-
samples with very low numbers of tumor cells, tumor pur-
ity is routinely assessed. The classical and clinically widely
used method is the manual evaluation of tissue sections
embedded on glass slides treated with an H&E dye that
visualizes individual cells and cell structures. By coloring
otherwise transparent tissue sections, microscopy viewing
of H&E-stained slides allows experienced pathologists and
researchers to distinguish different cell types, including
cancer cells, immune cells and fibroblasts. Unfortunately,
this approach is affected by inter- and intra-observer biases
[4]. The inclusion of tumor stroma can be avoided by using
methods such as laser-capture microdissection and high-
throughput cell sorting to isolate tumor cells, but these
approaches are time intensive and resource consuming
and for these reasons non-practical for clinical use and
have only limited applicability in the research setting.
Brenton and colleagues reasoned that an automated ap-
proach may lead to higher reproducibility and accuracy of
tumor purity prediction compared with manual assess-
ment. Immunohistochemistry stains of high-grade serous
ovarian cancer were matched with various molecular pro-
files that are available through The Cancer Genome Atlas
(TCGA) [1] and comparison of the image-based stromal
tissue estimates to those generated by a published and val-
idated mRNA signature based method [2] showed a sig-
nificant correlation, which suggested the accuracy of their
approach. In parallel, they performed semi-automated
analysis of ovarian carcinoma tissue microarray images
to associate tumor-specific phosphatase and tensin homo-
log (PTEN) protein expression levels with clinical out-
come in two independent large cohorts of ovarian cancer
(Study of Epidemiology and Risk Factors in Cancer Heredity
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consortium study [5]. The tissue microarrays provided
sufficient detail to allow scoring of PTEN expression in
tumor cells relative to that in stromal cells. As a result,
low absolute levels of tumor-specific PTEN expression
were observed in 77% of the SEARCH cohort and 52%
of the NOT cohort. Moreover, the authors showed that
reduced PTEN expression was significantly and inde-
pendently associated with clinical outcome as well as
PTEN copy number status in ovarian cancer. In sum-
mary, these findings suggested that PTEN is a putative
tumor suppressor gene in ovarian carcinoma.
The results by Brenton and colleagues highlight the
value of integrating H&E slide analysis, tumor purity and
genomic/transcriptomic analysis. One potential caveat of
this approach may be that the tissue sections used for
image analysis and genomic/transcriptomic analysis may
differ, resulting in discordant results. Ideally, H&E-stained
slides should be obtained from tumor areas in close
proximity to tumor tissue used for genomic/transcrip-
tomic analysis.
Clinical significance of PI3K/AKT signaling
Deactivation of PTEN through somatic mutations and
deletions is a common driver event of many cancers and
results in hyperactivation of the PI3K/AKT pathway. The
PI3K/AKT pathway regulates cell proliferation, survival,
and energy metabolism and key members such as PI3KCA,
AKT1, AKT2, AKT3, mTORC1 and mTORC2 provide at-
tractive therapeutic targets. DNA copy number analysis by
TCGA has suggested that focal amplifications of PIK3CA,
AKT1, AKT2 and AKT3 are frequent events in high-grade
serous ovarian carcinoma and provided earlier indications
that this pathway is commonly altered in this disease.
However, while functional studies confirmed the activation
of the PI3K/AKT axis through genetic alterations in ovar-
ian carcinoma, this does not ubiquitously confer sensitivity
to inhibitory signals, suggesting functional redundancy
of the pathway [6]. Acquired inactivation of PTEN can
provide resistance to PI3Kα inhibitors [7] and may
present an example of how disease critical pathways can
be double wired.
The TCGA analysis revealed that high-grade serous
ovarian cancer is characterized by TP53 mutation (96%),
homologous recombination deficiency (51%) and som-
atic or germline mutation of BRCA1 and BRCA2 (20%)
[1]. The frequent deactivation of homologous recombin-
ation pathways led to excitement over the possible appli-
cation of poly (ADP-ribose) polymerase (PARP) inhibitors
for treatment of ovarian carcinomas. PARP inhibitors
block DNA single-strand break repair, resulting in system-
atic lethality with homologous recombination deficiency
and are being tested in ovarian cancer clinical trials using
BRCA1/2 status as a biomarker (see ClinicalTrials.gov:NCT00753545, NCT01874353 and NCT01844986) [8].
PTEN loss also causes defects in repair of DNA double-
strand breaks by homologous recombination and may
provide an alternative mechanism of sensitivity to PARP
inhibitors [9]. Interestingly, combination of PARP and
PI3K inhibitors showed a synergistic antitumor effect in
PTEN-deficient prostate tumors [10]. A phase I study of
the PI3K inhibitor BKM120 and PARP inhibitor ola-
parib in patients with recurrent triple-negative breast
cancer and recurrent high-grade serous ovarian cancer
is underway (NCT01623349) and will provide important
early clinical data on whether this combination therapy
may provide a therapeutic advance. The standard of care
for patients with high-grade ovarian cancer has not
changed in several decades except for the relatively recent
addition of angiogenesis inhibitors such as bevacizumab.
The establishment of novel treatment modalities aimed at
molecular targets may lead to improvement of prognosis
for patients in dire need of better outcomes. Tumor-
specific PTEN protein expression may provide one aspect
of a multibiomarker panel that may guide the selection of
optimal therapy to inhibit the PI3K/AKT pathway.
Concluding remarks
A combination of genomic and image analyses has shed
light on the abrogation of PTEN which was hiding behind
a shade of tumor stroma and showed that loss of PTEN
function can be a driver event and prognostic factor in
high-grade serous ovarian cancer. These findings encour-
age us to re-evaluate the detection of tumor suppressor
genes after taking into consideration tumor purity.
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